2023
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity
2022
1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review
Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Khakwani K, Liu H, Hussain S, Singh P, Murad M, Bryce A. 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. Annals Of Oncology 2022, 33: s1193. DOI: 10.1016/j.annonc.2022.07.1903.Peer-Reviewed Original ResearchTreatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
Sipra Q, Bin Riaz I, Naqvi S, He H, Liu H, Bryce A, Murad M, McBane R. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis. Journal Of Clinical Oncology 2022, 40: e24070-e24070. DOI: 10.1200/jco.2022.40.16_suppl.e24070.Peer-Reviewed Original ResearchNet clinical benefitMixed treatment comparisonMajor bleedingClinical benefitSystematic reviewCANVAS trialOdds ratioGreater net clinical benefitRelevant non-major bleedingSignificant differencesTreatment comparisonsEffect estimatesEfficacy of DOACsNon-major bleedingVTE risk reductionVenous thromboembolism recurrenceCumulative ranking curvePatient-important outcomesConfidence intervalsMantel-Haenszel methodTreatment of catsFixed-effects modelThromboembolism recurrenceVTE recurrenceCause mortalityQuantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Riaz I, Sipra Q, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A, Murad M. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews In Oncology/Hematology 2022, 175: 103706. PMID: 35537621, DOI: 10.1016/j.critrevonc.2022.103706.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAbsolute benefitCell carcinomaTreatment-related grade 3Adjuvant treatment optionsHigher adverse eventsDisease-free survivalRisk-adapted strategyDelays disease progressionLarger tumor sizeEvidence synthesis frameworkAdjuvant therapyAdjuvant treatmentOverall survivalAdverse eventsNodal positivityLeibovich scoreTumor sizeTreatment optionsDisease progressionRisk groupsGrade 3Current evidenceComparative effectivenessSystematic review
2021
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-AnalysisA framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Maheswari D, Sipra Q, Montori V, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 335-335. DOI: 10.1200/jco.2021.39.6_suppl.335.Peer-Reviewed Original ResearchInteractive tableArtificial intelligenceJavaScript programming languageFive-layered architectureMetastatic renal cell carcinomaFirst-line metastatic renal cell carcinomaLine Metastatic Renal Cell CarcinomaProgramming languageProgression-free survivalDifferent teamsComplete responseOverall survivalSystematic reviewSearch strategyDynamic featuresNetworkEvidence synthesisInteractive networkFirst-line treatmentEvidence mapRenal cell carcinomaFrameworkShared-decision makingOverall responseBaseline characteristics